South West Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
Emergency Department, Liverpool Hospital, Sydney, New South Wales, Australia.
Acad Emerg Med. 2022 Jun;29(6):719-728. doi: 10.1111/acem.14446. Epub 2022 Mar 15.
The objective was to determine whether the use of fentanyl with ketamine for emergency department (ED) rapid sequence intubation (RSI) results in fewer patients with systolic blood pressure (SBP) measurements outside the pre-specified target range of 100-150 mm Hg following the induction of anesthesia. Methods This study was conducted in the ED of five Australian hospitals. A total of 290 participants were randomized to receive either fentanyl or 0.9% saline (placebo) in combination with ketamine and rocuronium, according to a weight-based dosing schedule. The primary outcome was the proportion of patients in each group with at least one SBP measurement outside the prespecified range of 100-150 mm Hg (with adjustment for baseline abnormality). Secondary outcomes included first-pass intubation success, hypotension, hypertension and hypoxia, mortality, and ventilator-free days 30 days following enrollment.
A total of 142 in the fentanyl group and 148 in the placebo group commenced the protocol. A total of 66% of patients receiving fentanyl and 65% of patients receiving placebo met the primary outcome (difference = 1%, 95% CI = -10 to 12). Hypotension (SBP ≤ 99 mm Hg) was more common with fentanyl (29% vs. 16%; difference = 13%, 95% CI = 3% to 23%), while hypertension (≥150 mm Hg) occurred more with placebo (69% vs. 55%; difference = 14%, 95% CI = 3 to 24). First-pass success rate, 30 day mortality, and ventilator-free days were similar.
There was no difference in the primary outcome between groups, although lower blood pressures were more common with fentanyl. Clinicians should consider baseline hemodynamics and postinduction targets when deciding whether to use fentanyl as a coinduction agent with ketamine.
确定在诱导麻醉后,接受芬太尼联合氯胺酮用于急诊科(ED)快速序贯插管(RSI)的患者中,与接受 0.9%生理盐水(安慰剂)联合氯胺酮和罗库溴铵的患者相比,收缩压(SBP)测量值在 100-150mmHg 预设目标范围内的患者比例是否更少。方法:本研究在澳大利亚的五家医院的 ED 进行。根据基于体重的剂量方案,共 290 名参与者被随机分为接受芬太尼或 0.9%生理盐水(安慰剂)联合氯胺酮和罗库溴铵。主要结局是每组中至少有一次 SBP 测量值超出 100-150mmHg 预设范围的患者比例(调整基线异常)。次要结局包括首次插管成功、低血压、高血压和缺氧、死亡率以及入组后 30 天无呼吸机天数。
共 142 名接受芬太尼的患者和 148 名接受安慰剂的患者开始了该方案。接受芬太尼的患者中有 66%,接受安慰剂的患者中有 65%符合主要结局(差异=1%,95%CI=-10 至 12)。芬太尼更常见低血压(SBP≤99mmHg)(29%比 16%;差异=13%,95%CI=3%至 23%),而安慰剂更常见高血压(≥150mmHg)(69%比 55%;差异=14%,95%CI=3 至 24)。首次插管成功率、30 天死亡率和无呼吸机天数相似。
两组之间主要结局无差异,尽管芬太尼更常见血压较低。当决定是否使用芬太尼作为氯胺酮的联合诱导剂时,临床医生应考虑基线血流动力学和诱导后目标。